<DOC>
	<DOCNO>NCT02527668</DOCNO>
	<brief_summary>Young postmenopausal woman osteopenia / woman osteoporosis FRAX score pharmacologic treatment indication limit treatment option prevention osteoporosis/treatment osteopenia . Further , concern long-term side effect bisphosphonate treatment among young postmenopausal woman , hormone replacement therapy controversial . In pilot study 20 microgram Calcifediol Hy.D improve several muscle relate function target population within 4 month treatment , help prevent fall associate bone fracture . Thus main aim study test whether Calcifediol Hy.D daily dose 20 μg / day improve muscle function ( low extremity test battery ) compare ( 1 ) placebo compare ( 2 ) 3200 Vitamin D3 IU per day , 3 6 month follow-up . As secondary exploratory objective study , investigator compare beforementioned dos muscle strength quality bone , beside muscle mass , body composition systolic diastolic blood pressure measurement .</brief_summary>
	<brief_title>To Test Effect Calcifediol Hy.D Supplementation Muscle Function Bone Quality Younger Postmenopausal Women With Osteopenia</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Hydroxycholecalciferols</mesh_term>
	<mesh_term>Calcifediol</mesh_term>
	<criteria>Women age 50 70 Postmenopausal ( define : least 1 year last menstrual period ) communitydwelling ambulatory without help document osteopenia ( BMD DEXA tscore : &lt; 1.0 &gt; 2.5 spine hip ) 6 month prior enrolment document osteoporosis ( BMD DEXA tscore : ≤ 2.5 spine hip ) FRAX score ( online calculation tool absolute 10 year fracture risk ) Swiss agedependent indication threshold pharmacologic treatment 10year risk major osteoporotic fracture screen visit include DEXA ( 6 month prior enrolment ) part calculation body mass index &gt; 18.5 &lt; 30 kg/m2 25 ( OH ) D level &lt; 24 µg/l ( &lt; 60 nmol/l ) understand German read write plus able read , understand , complete questionnaire test willingness limit additional vitamin D3 intake 800 IU per day willingness limit calcium supplement intake 500 mg/day willingness stop active vitamin D metabolites participant understands study procedure , alternative treatment available risk involve study voluntarily agree participate give write informed consent participant meet routine clinical laboratory safety screen test perform screen visit participant able willing perform study test , attend require office visit , provide blood urine sample participant able swallow study medication Consumption 1'000 IU vitamin D day 4 week prior enrollment . Elevated serum calcium &gt; 2.60 mmol/l adjust albumin albumin ≤ 35 ≥ 45g/l estimate creatinine clearance &lt; 30 ml/min ( Cockcroft Gault = 140 age ( yr ) *weight ( kg ) / serum Cr ( mmol/l ) ) × ( 1.04 woman ) severe visual hearing impairment malabsorption syndrome ( celiac disease , inflammatory bowel disease ) . Pathologic fracture ( excl . fracture due osteoporosis ) last year Fracture due osteoporosis last 10 year Chemo therapy / Radiation due cancer last year Treatment effect calcium metabolism ( e.g . PTH , calcitonin , chronic cortisone intake &gt; 5mg/day 4 week last 12 month ( except inhalation sporadic infiltration ) ) Current treatment bisphosphonate For participant ancillary study `` Muscle Biopsy '' : Treatment effect blood coagulation ( e.g . factor X inhibitor , thrombin inhibitor , NSAR , lowmolecular heparin , inhibitor platelet aggregation , vitamin K antagonist ) and/or abnormal blood coagulation status . Unwilling unable take study medication Diseases risk recurrent fall ( e.g . Parkinson 's disease/syndrome , Hemiplegia stroke , symptomatic stenosis spinal canal , polyneuropathy , epilepsy , recur vertigo , recur syncope ) History current disease may enhance serum calcium : sarcoidosis , lymphoma , primary hyperparathyroidism Individual heavily consume alcohol contain product define great ( &gt; ) 3 drink ( beer , wine , distilled spirit ) alcoholic beverage per day . Individual unlikely adhere study procedure , keep appointment , plan relocate study . Individuals plan stay `` sunny '' location ( e.g . winter sun resort ) one month course study Medication effect 25hydroxyvitamin D level ( e.g . certain anticonvulsant ( e.g . Phenobarbital , Carbamazepin , Phenytoin ) ) M. Paget ( Ostitis deformans ) Inflammatory arthritis ( e.g . rheumatoid arthritis , Reiter syndrome , psoriasis arthritis ) Participation study last 6 month , except study without drugapplication , influence studymedication exclude</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>